CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
Studies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD studied compared to tiotropium, olodaterol and placebo[1]
Additionally, night-time rescue medication use and shortness of breath has been reduced with Spiolto® Respimat® [2,3]
From early in the course of COPD, decreasing lung function makes it more and more difficult for patients to breathe. When many patients are first diagnosed their condition is already declining rapidly. To cope with feeling breathless, patients reduce their activity and change their lifestyles. Once symptoms start to prevent normal daily activities there is a downward spiral of reduced physical activity leading to worsening symptoms, further dyspnea and even further sedentary behavior.[4] This in turn results in a large physical and emotional impact on people living with the disease.[5]
“The post-hoc data presented at the CHEST meeting demonstrate that Spiolto® Respimat® may provide improvement across several important clinical outcomes. These results further support the evidence of the benefit of using Spiolto® Respimat® in patients requiring COPD maintenance treatment. Providing optimal treatment right from the start of maintenance therapy can give patients the best chance of managing their symptoms, keeping active and limiting their need for rescue medication ”, said Dr William Mezzanotte, Vice President and Head of Respiratory Medicine at Boehringer Ingelheim.
The most common adverse events in the TONADO® 1&2 and OTEMTO® 1&2 studies were nasopharyngitis (common cold), cough and back pain.
For more information see US press release: http://us.boehringer-ingelheim.com/news_events/press_releases/press_release_archive/2015/10-27-2015-new-sub-analyses-presented-stiolto-respimat-across-range-patient-reported-outcomes-measures.html
For further information visit: http://newscentre.boehringer-ingelheim.com/education_hub1/respiratory.html
OTEMTO® Respiratory Medicine publication: http://dx.doi.org/10.1016/j.rmed.2015.08.002
For ‘Notes to Editors’ and ‘References’ please visit: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/28_october_2015_copd.html
* Patients requiring maintenance treatment
View source version on businesswire.com: http://www.businesswire.com/news/home/20151028005663/en/
Website: http://www.boehringer-ingelheim.com
Contact
Boehringer Ingelheim
Dr. Kristin Jakobs
Media & PR
+49 6132 77 144553
press@boehringer-ingelheim.com
This news is a press release provided by Boehringer Ingelheim International GmbH.
-
2021년 9월 10일 15:15
-
2021년 3월 2일 15:05